The favorable survival after resection of IPMN-associated invasive adenocarcinoma (dotted line) compared with standard ductal adenocarcinoma (continuous line) was mainly noted in patients with node negative (N0) disease (median survival, 92 vs. 25 months) and T1 tumors (median survival, not reached vs. 26 months). However, in patients with node positive disease (N1, 20 vs. 18 months) and tumors >2 cm and/or extrapancreatic extension, survival outcomes were similar (median, T2: 45 vs. 34 months; T3: 23 vs. 19 months; T4: 19 vs. 10 months).